Scott Rocklage | PhD
Scott joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. He has over three decades of healthcare management experience with strategic leadership [...]
Scott joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. He has over three decades of healthcare management experience with strategic leadership [...]
Loredana joined Nouscom in 2020 as the Technical Director from Reithera. She has fifteen years of industry experience spanning process development and GMP production of viral vectored vaccines. [...]
John has over 25 years of business development experience with some of the industry’s premier companies, including Genentech, Genzyme, Millennium Pharmaceuticals, MPM Capital, Biogen and [...]
Vincent has more than 25 years’ experience in the oncology and immunology field, including almost 15 years at GlaxoSmithKline (“GSK”) where he was Senior Vice-President and had responsibility for [...]
Jean-Paul served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011. Jean-Paul joined GlaxoSmithKline Biologicals in 1987 [...]
BASEL, Switzerland – 15th March 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new [...]
8th March 2023 – We are glad to announce the following promotions of our team members: Loredana Siani to Vice President of Technical and CMC Development, Tiffany Brooke Muller to Senior [...]
1st March 2023 -We are thrilled to welcome Sarah Runswick as Senior Director of Clinical Science at Nouscom. Sarah is an experienced global clinical scientist with over 20 years expertise in [...]
19th January 2023 -We are thrilled to welcome Yen-Ching Chua as VP of Clinical Operations at Nouscom. Yen-Ching is an experienced global clinical operations leader with over 20 years expertise in [...]
BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
